Alpha 2.0
Login Register
» Authors » Luis Fein

Luis Fein

Explore the profile of Luis Fein including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 1605
Followers 0
Related Specialties
Oncology
General Medicine
Gastroenterology
Top 10 Co-Authors
Andrew Protheroe
Karim Fizazi
NamPhuong Tran
Alfredo Rodriguez-Antolin
Mustafa Ozguroglu
Nobuaki Matsubara
Kim N Chi
Susan Feyerabend
Boris Y Alekseev
Shem J Patyna
Published In
Lancet Oncol
J Clin Oncol
Clin Drug Investig
J Hepatobiliary Pancreat Surg
Clin Colorectal Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials
Borrego M, Lu Y, Reyes-Cosmelli F, Park Y, Yamashita T, Chiu J, et al.
Breast Cancer Res Treat . 2024 Aug; 208(1):111-121. PMID: 39177931
Purpose: Alpelisib plus fulvestrant demonstrated a significant progression-free survival benefit versus fulvestrant in patients with PIK3CA-mutated HR+ /HER2- advanced breast cancer (ABC) (SOLAR-1). Hyperglycemia, an on-target adverse effect of PI3Kα...
2.
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with V600-mutant melanoma with brain metastasis
Menzies A, Long G, Kohn A, Tawbi H, Weber J, Flaherty K, et al.
Neurooncol Adv . 2024 May; 6(1):vdae033. PMID: 38725995
Background: POLARIS (phase 2 [ph2]; NCT03911869) evaluated encorafenib (BRAF inhibitor) in combination with binimetinib (MEK1/2 inhibitor) in BRAF/MEK inhibitor-naïve patients with V600-mutant melanoma with asymptomatic brain metastases. Methods: The safety...
3.
Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Fein L, Lazaretti N, Chuken Y, Benfield J, Mano M, Lobaton J, et al.
Clin Drug Investig . 2023 Sep; 43(9):707-708. PMID: 37695417
No abstract available.
4.
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Fein L, Lazaretti N, Chuken Y, Benfield J, Mano M, Lobaton J, et al.
Clin Drug Investig . 2023 Aug; 43(9):699-706. PMID: 37594640
Background And Objectives: Palbociclib is a cyclin-dependent kinase 4/6 inhibitor that is approved in the United States for the treatment of hormone receptor‒positive (HR+)/human epidermal growth factor receptor‒2 negative (HER2-)...
5.
Attitudes and beliefs of Argentinian medical oncologists regarding palliative care referral
Sala R, Dran G, Bruera E, Niccolai B, Fein E, Romera A, et al.
Medicina (B Aires) . 2023 Feb; 83(1):10-18. PMID: 36774592
Introduction: Local evidence suggests insufficient access to palliative care (PC) for advanced cancer patients. The objective was to investigate the attitudes and beliefs of Argentinian medical oncologists regarding PC referral...
6.
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Rugo H, Umanzor G, Barrios F, Vasallo R, Chivalan M, Bejarano S, et al.
J Clin Oncol . 2022 Jul; 41(1):65-74. PMID: 35858154
Purpose: Intravenous paclitaxel (IVpac) is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions. Paclitaxel is poorly absorbed orally; encequidar (E), a novel P-glycoprotein pump inhibitor, allows oral absorption....
7.
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen...
Matsubara N, Chi K, Ozguroglu M, Rodriguez-Antolin A, Feyerabend S, Fein L, et al.
Eur Urol . 2019 Dec; 77(4):494-500. PMID: 31843335
Background: LATITUDE, a randomized, double-blind trial, compared abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in high-risk metastatic castration-sensitive prostate cancer (mCSPC). Objective:...
8.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B, et al.
Lancet Oncol . 2019 Apr; 20(5):686-700. PMID: 30987939
Background: In the interim analyses of the LATITUDE study, the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant improvement in overall survival and...
9.
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B, et al.
N Engl J Med . 2017 Jun; 377(4):352-360. PMID: 28578607
Background: Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with...
10.
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Gomez H, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, et al.
Clin Breast Cancer . 2015 Dec; 16(1):38-44. PMID: 26642810
Background: Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives...